{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:12:05Z","timestamp":1788221525113,"version":"build-2803163510"},"posted":{"date-parts":[[2025,11,3]]},"group-title":"Biochemistry","reference-count":39,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"award":["R35 GM140837-01"],"award-info":[{"award-number":["R35 GM140837-01"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["5T32GM132029-06"],"award-info":[{"award-number":["5T32GM132029-06"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["T32GM008347"],"award-info":[{"award-number":["T32GM008347"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Proteolysis targeting chimeras (PROTACs) are an emerging therapeutic modality that induces protein degradation by recruiting E3 ligases. Most reported PROTACs recruit ubiquitously expressed E3 ligases, such as cereblon and the von Hippel-Lindau tumor suppressor. Of the additional 600+ E3 ligases, recruiting those with tissue-restricted expression is attractive for increasing the specificity of PROTACs. To this end, tissue-specific E3 ligases or E3 ligase-associated proteins that can be recruited for targeted protein degradation need to be identified. This work describes the first reported PROTAC that recruits the tissue-specific E3 ligase scaffolding protein MAGEA11. As an initial demonstration, a library of bromodomain and extra-terminal domain (BET)-targeting PROTACs that recruit MAGEA11 was synthesized. The library was screened in osteosarcoma U2OS cells, identifying lead compound 105B. 105B potently degrades BET proteins in U2OS osteosarcoma cell lines (BRD4 DC\n                  <jats:sub>50<\/jats:sub>\n                  = 0.130 nM, D\n                  <jats:sub>max<\/jats:sub>\n                  = 78%) and KYSE180 esophageal squamous cell carcinoma cell lines (DC\n                  <jats:sub>50<\/jats:sub>\n                  = 40 nM, D\n                  <jats:sub>max<\/jats:sub>\n                  = 70%), but shows no degradation in non-cancerous, MAGEA11-deficient HEK293T cells. Mechanistic studies confirmed 105B\u2019s dependence on the ubiquitin-proteasome system and engagement of both MAGEA11 and BRD4. 105B decreased levels of BET-regulated gene products c-Myc, RUNX2, and KRT14; however, improvements are still necessary to affect selective cytotoxicity. This work reports the first example of a PROTAC recruiting a tissue-specific E3 ligase for cancer-restricted degradation of BET proteins and highlights the need for further development of MAGEA11-recruiting degraders.\n                <\/jats:p>","DOI":"10.1101\/2025.11.03.686228","type":"posted-content","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:15:15Z","timestamp":1762190115000},"source":"Crossref","is-referenced-by-count":1,"title":["Design of Tissue-Selective PROTACs Through Recruiting E3 Ligase Scaffolding Protein MAGEA11"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0688-7119","authenticated-orcid":false,"given":"Isabella E.","family":"Jacobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3654-5075","authenticated-orcid":false,"given":"Cole R.","family":"Scholtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.K.","family":"Pomerantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8900-9460","authenticated-orcid":false,"given":"Gunda I.","family":"Georg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025110509101449000_2025.11.03.686228v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"2025110509101449000_2025.11.03.686228v1.2","doi-asserted-by":"crossref","unstructured":"Liu, Z. , Hu, M. , Yang, Y. , Du, C. , Zhou, H. , Liu, C. , Chen, Y. , Fan, L. , Ma, H. , Gong, Y. , Xie, Y. An overview of PROTACs: A promising drug discovery paradigm. Mol. Biomed. 2022, 3 (1).","DOI":"10.1186\/s43556-022-00112-0"},{"key":"2025110509101449000_2025.11.03.686228v1.3","doi-asserted-by":"crossref","unstructured":"Li, X. , Pu, W. , Zheng, Q. , Ai, M. , Chen, S. , Peng, Y. Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Mol. Cancer 2022, 21 (1).","DOI":"10.1186\/s12943-021-01434-3"},{"key":"2025110509101449000_2025.11.03.686228v1.4","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00216"},{"key":"2025110509101449000_2025.11.03.686228v1.5","doi-asserted-by":"crossref","unstructured":"Smith, B. E. , Wang, S. L. , Jaime-Figueroa, S. , Harbin, A. , Wang, J. , Hamman, B. D. , Crews, C. M. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat. Commun. 2019, 10 (1).","DOI":"10.1038\/s41467-018-08027-7"},{"key":"2025110509101449000_2025.11.03.686228v1.6","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00092"},{"key":"2025110509101449000_2025.11.03.686228v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2329"},{"key":"2025110509101449000_2025.11.03.686228v1.8","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.9b06422"},{"issue":"5","key":"2025110509101449000_2025.11.03.686228v1.9","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/jacs.9b12718","article-title":"Optical control of small molecule-induced protein degradation","volume":"142","year":"2020","journal-title":"J. Am. Chem. Soc"},{"key":"2025110509101449000_2025.11.03.686228v1.10","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay5154"},{"key":"2025110509101449000_2025.11.03.686228v1.11","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.0c00285"},{"key":"2025110509101449000_2025.11.03.686228v1.12","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.1c00451"},{"key":"2025110509101449000_2025.11.03.686228v1.13","doi-asserted-by":"crossref","first-page":"112397","DOI":"10.1016\/j.ejmech.2020.112397","article-title":"Discovery of IAP-recruiting BCL-xL PROTACs as potent degraders across multiple cancer cell lines","volume":"199","year":"2020","journal-title":"Eur. J. Med. Chem"},{"key":"2025110509101449000_2025.11.03.686228v1.14","doi-asserted-by":"publisher","DOI":"10.1039\/D2CS00200K"},{"key":"2025110509101449000_2025.11.03.686228v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2015.08.002"},{"key":"2025110509101449000_2025.11.03.686228v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.12.022"},{"key":"2025110509101449000_2025.11.03.686228v1.17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.008029"},{"key":"2025110509101449000_2025.11.03.686228v1.18","doi-asserted-by":"publisher","DOI":"10.1002\/jor.1100150119"},{"key":"2025110509101449000_2025.11.03.686228v1.19","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-08-0400"},{"issue":"3","key":"2025110509101449000_2025.11.03.686228v1.20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.arcmed.2016.06.001","article-title":"Prognostic significance of MAGE-A11 in esophageal squamous cell carcinoma and identification of related genes based on DNA microarray","volume":"47","year":"2016","journal-title":"Arch. Med. Res"},{"issue":"2","key":"2025110509101449000_2025.11.03.686228v1.21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.lungcan.2006.12.004","article-title":"Differential expression profile of MAGE family in non-small-cell lung cancer","volume":"56","year":"2007","journal-title":"Lung Cancer"},{"key":"2025110509101449000_2025.11.03.686228v1.22","doi-asserted-by":"crossref","unstructured":"Wang, Z.-Q. , Zhang, Z.-C. , Wu, Y.-Y. , Pi, Y.-N. , Lou, S.-H. , Liu, T.-B. , Lou, G. , Yang, C. Bromodomain and extraterminal (BET) proteins: Biological functions, diseases, and targeted therapy. Signal Transduction Targeted Ther. 2023, 8 (1).","DOI":"10.1038\/s41392-023-01647-6"},{"issue":"4","key":"2025110509101449000_2025.11.03.686228v1.23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/med.21942","article-title":"Recent progress and structural analyses of domain-selective bet inhibitors","volume":"43","year":"2023","journal-title":"Med. Res. Rev"},{"key":"2025110509101449000_2025.11.03.686228v1.24","doi-asserted-by":"crossref","unstructured":"Pomerantz, W. C. K. , Johnson, J. A. , Ycas, P. D. Applied biophysics for bromodomain drug discovery. Springer International Publishing, 2019; pp 287\u2013337.","DOI":"10.1007\/7355_2019_79"},{"key":"2025110509101449000_2025.11.03.686228v1.25","doi-asserted-by":"crossref","unstructured":"Lamoureux, F. , Baud\u2019Huin, M. , Rodriguez Calleja, L. , Jacques, C. , Berreur, M. , R\u00e9dini, F. , Lecanda, F. , Bradner, J. E. , Heymann, D. , Ory, B. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat. Commun. 2014, 5 (1).","DOI":"10.1038\/ncomms4511"},{"key":"2025110509101449000_2025.11.03.686228v1.26","doi-asserted-by":"crossref","unstructured":"Niu, H. , Wei, H. , Zhou, X. , Liu, Y. , Yang, L. , Wang, Q. , Luo, B. , Luo, Q. , Song, F. BRD4 induces esophageal squamous cell carcinoma progression via the wnt\/\u03b2-catenin pathway. Biochem. Genet. 2025.","DOI":"10.1007\/s10528-025-11043-0"},{"key":"2025110509101449000_2025.11.03.686228v1.27","doi-asserted-by":"crossref","unstructured":"Yang, S. W. , Huang, X. , Lin, W. , Min, J. , Miller, D. J. , Mayasundari, A. , Rodrigues, P. , Griffith, E. C. , Gee, C. T. , Li, L. , Li, W. , Lee, R. E. , Rankovic, Z. , Chen, T. , Potts, P. R. Structural basis for substrate recognition and chemical inhibition of oncogenic MAGE ubiquitin ligases. Nat. Commun. 2020, 11 (1).","DOI":"10.1038\/s41467-020-18708-x"},{"key":"2025110509101449000_2025.11.03.686228v1.28","doi-asserted-by":"crossref","unstructured":"Wu, D. , Yin, H. , Yang, C. , Zhang, Z. , Fang, F. , Wang, J. , Li, X. , Xie, Y. , Hu, X. , Zhuo, R. , Chen, Y. , Yu, J. , Li, T. , Li, G. , Pan, J. The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma. BMC Cancer 2024, 24 (1).","DOI":"10.1186\/s12885-024-12691-y"},{"key":"2025110509101449000_2025.11.03.686228v1.29","unstructured":"Mage-a11. The Human Protein Atlas, https:\/\/www.proteinatlas.org\/ENSG00000185247-MAGEA11 (accessed 2024 09\/16)."},{"issue":"7","key":"2025110509101449000_2025.11.03.686228v1.30","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/s41418-021-00751-w","article-title":"Bromodomain protein BRDT directs \u03b4Np63 function and super-enhancer activity in a subset of esophageal squamous cell carcinomas","volume":"28","year":"2021","journal-title":"Cell Death Differ"},{"key":"2025110509101449000_2025.11.03.686228v1.31","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.4c00450"},{"key":"2025110509101449000_2025.11.03.686228v1.32","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.8b00692"},{"key":"2025110509101449000_2025.11.03.686228v1.33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1919507117"},{"issue":"36","key":"2025110509101449000_2025.11.03.686228v1.34","doi-asserted-by":"crossref","first-page":"24884","DOI":"10.1021\/jacs.4c05393","article-title":"Development of ligands and degraders targeting MAGE-A3","volume":"146","year":"2024","journal-title":"J. Am. Chem. Soc"},{"key":"2025110509101449000_2025.11.03.686228v1.35","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00506"},{"key":"2025110509101449000_2025.11.03.686228v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2015.05.009"},{"issue":"11","key":"2025110509101449000_2025.11.03.686228v1.37","first-page":"3590","article-title":"E2F-1 up-regulates c-Myc and p14ARF and induces apoptosis in colon cancer cells","volume":"7","year":"2001","journal-title":"Clin. Cancer Res"},{"key":"2025110509101449000_2025.11.03.686228v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2016.10.006"},{"key":"2025110509101449000_2025.11.03.686228v1.39","doi-asserted-by":"crossref","unstructured":"Troup, R. I. , Fallan, C. , Baud, M. G. J. Current strategies for the design of PROTAC linkers: A critical review. Explor. Targeted Anti-tumor Ther. 2020, 1 (5).","DOI":"10.37349\/etat.2020.00018"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.11.03.686228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:56:52Z","timestamp":1768471012000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.11.03.686228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1101\/2025.11.03.686228","relation":{},"subject":[],"published":{"date-parts":[[2025,11,3]]},"subtype":"preprint"}}